CIK 0001501989 · Accelerated filer
CytomX Therapeutics, Inc.
Sign in to watch- Ticker
- CTMX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 273521219
- Phone
- 650.515.3185
- Business address
- 151 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO, CA, 94080
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-02-02 | Ogden Christopher SVP, Finance and Accounting | Grant or award | +25,000 | 38,288 | ||
| 2023-02-02 | Ogden Christopher SVP, Finance and Accounting | Grant or award · Stock Option (Right to Buy) | +75,000 | 75,000 | ||
| 2023-02-02 | Ogden Christopher SVP, Finance and Accounting | Grant or award · Performance Stock Units (PSUs) | +75,000 | 75,000 | ||
| 2022-08-10 | McCarthy Sean A. CEO | Grant or award · Stock Option (Right to Buy) | +450,000 | 450,000 | ||
| 2022-08-10 | McCarthy Sean A. CEO | Grant or award · Performance Stock Units (PSUs) | +75,000 | 75,000 | ||
| 2022-08-10 | Landau Jeffrey B Chief Business Officer | Grant or award · Stock Option (Right to Buy) | +135,000 | 135,000 | ||
| 2022-08-10 | Landau Jeffrey B Chief Business Officer | Grant or award · Performance Stock Units (PSUs) | +22,500 | 22,500 | ||
| 2022-08-10 | Ogden Christopher SVP, Finance and Accounting | Grant or award · Stock Option (Right to Buy) | +82,500 | 82,500 | ||
| 2022-08-10 | Ogden Christopher SVP, Finance and Accounting | Grant or award · Performance Stock Units (PSUs) | +13,750 | 13,750 | ||
| 2022-08-10 | ROWLAND LLOYD A General Counsel | Grant or award · Stock Option (Right to Buy) | +135,000 | 135,000 | ||
| 2022-08-10 | ROWLAND LLOYD A General Counsel | Grant or award · Performance Stock Units (PSUs) | +22,500 | 22,500 | ||
| 2022-07-20 | Peterson Amy C. EVP, Chief Development Officer | Sale | −7,463 | $1.42 | $11K | 62,690 |
| 2022-07-20 | Landau Jeffrey B Chief Business Officer | Sale | −4,206 | $1.42 | $6K | 30,725 |
| 2022-07-20 | McCarthy Sean A. President and CEO | Sale | −14,911 | $1.42 | $21K | 290,942 |
| 2022-07-20 | ROWLAND LLOYD A General Counsel | Sale | −5,602 | $1.42 | $8K | 43,689 |
| 2022-07-20 | HANNAH ALISON L. Chief Medical Officer | Sale | −5,602 | $1.42 | $8K | 31,898 |
| 2022-07-20 | Campoy Carlos Chief Financial Officer | Sale | −3,949 | $1.42 | $6K | 39,972 |
| 2022-07-19 | Peterson Amy C. EVP, Chief Development Officer | Grant or award | +20,000 | 70,153 | ||
| 2022-07-19 | Landau Jeffrey B Chief Business Officer | Grant or award | +11,250 | 34,931 | ||
| 2022-07-19 | McCarthy Sean A. President and CEO | Grant or award | +40,000 | 305,853 |
Page 10 of 33 · 649 trades